MDACC Study No:2013-0036 ( NCT No: NCT01696045)
Title:A Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 years) with
Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant
Principal Investigator:Cynthia E. Herzog
Treatment Agent:Ipilimumab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if Yervoy™ (ipilimumab)
can help to control metastatic melanoma. The safety of this drug will also be

Ipilimumab is designed to increase the immune system's ability to fight cancer.
The drug blocks a molecule that is believed to shut down the part of the immune
system that attacks cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Melanoma; Pediatrics
Phase of Study:Phase II
Treatment Agents:Ipilimumab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristo-Myers Squibb
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Cynthia E. Herzog
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults